A novel fusion variant LSM14A::NR4A3 in extraskeletal myxoid chondrosarcoma

Genes Chromosomes Cancer. 2023 Jan;62(1):52-56. doi: 10.1002/gcc.23090. Epub 2022 Aug 22.

Abstract

Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue neoplasm of uncertain lineage characterized by the pathognomonic rearrangement of the NR4A3 gene, which in most cases is fused with EWSR1. Other NR4A3 fusion partners have been described, namely TAF15, FUS, TCF12, and TGF. Some studies suggest that EMCs with non-EWSR1 variant fusion are associated with high-grade morphology and worst clinical behavior compared to EWSR1::NR4A3 tumors, supporting the potential significance of particular fusion variant in EMC. We report a case of a 34-year-old male who presented with calf EMC and subsequently developed a slowly progressive metastatic disease 3 years after diagnosis. Whole-transcriptome analysis with total RNA sequencing enabled identification of a novel fusion transcript LSM14A::NR4A3, expanding the molecular spectrum of EMC.

Keywords: LSM14A::NR4A3; extraskeletal myxoid chondrosarcoma; gene fusion.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chondrosarcoma* / pathology
  • DNA-Binding Proteins
  • Humans
  • Male
  • Oncogene Proteins, Fusion / genetics
  • Receptors, Steroid* / genetics
  • Receptors, Thyroid Hormone / genetics
  • Soft Tissue Neoplasms* / genetics

Substances

  • Receptors, Thyroid Hormone
  • Receptors, Steroid
  • Oncogene Proteins, Fusion
  • NR4A3 protein, human
  • DNA-Binding Proteins

Supplementary concepts

  • Chondrosarcoma, Extraskeletal Myxoid